Richard I Steinhart Bio Xcel Therapeutics, Inc. (BTAI) insider trading activity

Richard I Steinhart is Chief Financial Officer of BioXcel Therapeutics, Inc.. Currently has a direct ownership of 6,441 shares of BTAI, which is worth approximately $43,798. The most recent transaction as insider was on Jul 22, 2025, when has been sold 625 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 6.44K

369.12% 3M change

17.62% 12M change

Total Value Held $43,798

Richard I Steinhart Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 22 2025	BUY Exercise of conversion of derivative security	-	625 Added 8.85%	6,441 Common Stock
Jul 22 2025	BUY Grant, award, or other acquisition	-	4,375 Added 42.93%	5,816 Common Stock
Jun 15 2025	BUY Exercise of conversion of derivative security	-	35 Added 2.37%	1,441 Common Stock
Jun 14 2025	BUY Exercise of conversion of derivative security	-	33 Added 2.29%	1,406 Common Stock
Mar 15 2025	BUY Exercise of conversion of derivative security	-	34 Added 2.42%	1,373 Common Stock
Mar 14 2025	BUY Exercise of conversion of derivative security	-	31 Added 2.26%	1,339 Common Stock
Dec 16 2024	SELL Open market or private sale	$207 $0.36 p/Share	577 Reduced 2.68%	20,932 Common Stock
Dec 15 2024	BUY Exercise of conversion of derivative security	-	562 Added 2.56%	21,362 Common Stock
Dec 14 2024	BUY Exercise of conversion of derivative security	-	521 Added 2.44%	20,800 Common Stock
Oct 03 2024	SELL Open market or private sale	$3,946 $0.55 p/Share	7,175 Reduced 26.13%	20,279 Common Stock
Sep 17 2024	BUY Grant, award, or other acquisition	-	21,250 Added 43.63%	27,454 Common Stock
Sep 16 2024	SELL Open market or private sale	$245 $0.69 p/Share	356 Reduced 5.43%	6,204 Common Stock
Sep 15 2024	BUY Exercise of conversion of derivative security	-	563 Added 7.9%	6,560 Common Stock
Sep 14 2024	BUY Exercise of conversion of derivative security	-	521 Added 7.99%	5,997 Common Stock
Jun 17 2024	SELL Open market or private sale	$468 $1.26 p/Share	372 Reduced 6.36%	5,476 Common Stock
Jun 15 2024	BUY Exercise of conversion of derivative security	-	562 Added 8.77%	5,848 Common Stock
Jun 14 2024	BUY Exercise of conversion of derivative security	-	521 Added 8.97%	5,286 Common Stock
Apr 04 2024	SELL Open market or private sale	$2,811 $2.63 p/Share	1,069 Reduced 18.32%	4,765 Common Stock
Mar 15 2024	BUY Exercise of conversion of derivative security	-	2,250 Added 27.83%	5,834 Common Stock
Mar 14 2024	BUY Exercise of conversion of derivative security	-	521 Added 12.69%	3,584 Common Stock
Dec 14 2023	BUY Exercise of conversion of derivative security	-	521 Added 14.54%	3,063 Common Stock
Sep 14 2023	BUY Exercise of conversion of derivative security	-	521 Added 17.01%	2,542 Common Stock
Jun 14 2023	BUY Exercise of conversion of derivative security	-	521 Added 20.5%	2,021 Common Stock
May 15 2023	SELL Open market or private sale	$135,850 $27.17 p/Share	5,000 Reduced 76.92%	1,500 Common Stock
May 14 2023	BUY Exercise of conversion of derivative security	-	5,000 Added 43.48%	6,500 Common Stock

Also insider at

ATOS

ATOSSA THERAPEUTICS, INC. Healthcare

ATNM

Actinium Pharmaceuticals, Inc. Healthcare

Director

RIS